Retatrutide: The Complete Guide
The first peptide ever designed to activate three metabolic receptors at the same time — GIP, GLP-1, and glucagon. The most advanced compound in current obesity research, with Phase 3 trial data showing the largest body-weight effects ever reported for a metabolic peptide.
What is Retatrutide?
Here is the simplest way to understand Retatrutide: if Tirzepatide added a second hormone receptor to the metabolic peptide story, Retatrutide adds a third. Tirzepatide rings two doorbells at once (GIP and GLP-1) — both hormones the gut releases after meals to say "we are full." Retatrutide rings those same two doorbells plus a third one called glucagon. And the third voice in the harmony does something different from the first two.
Glucagon does not say "we are full" — it says "burn what you have." Where GIP and GLP-1 reduce appetite and slow gastric emptying, glucagon increases energy expenditure. The body burns more of its existing fuel reserves. This is the piece that no metabolic peptide before Retatrutide had ever combined with the appetite-suppressing pathways. Research suggests the result is a compound that works on both sides of the energy equation simultaneously — eating less and burning more, through the same molecule.
Eli Lilly developed Retatrutide as the next evolution of their metabolic peptide programme — the same lab that built Tirzepatide. The TRIUMPH Phase 3 programme runs across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular outcomes, and metabolic liver disease. Several trials have now reported: TRIUMPH-4 in December 2025, TRIUMPH-1 in May 2026 (up to 28.3% mean body-weight reduction at 80 weeks across 2,339 participants), and TRIUMPH-2 and TRIUMPH-3 in July 2026. Eli Lilly has stated it intends to file with the FDA in the first quarter of 2027. Retatrutide holds no approval from the FDA, EMA or TGA.
Research Applications
Research on Retatrutide is at the most active stage in metabolic peptide development right now. Phase 3 trials are running across multiple indications, with Phase 2 data already published in obesity, type 2 diabetes, and metabolic liver disease. Here is where the research has focused:
Research suggests the triple-agonist approach produces effects single and dual-receptor compounds cannot match. GIP and GLP-1 reduce appetite and slow digestion. Glucagon increases energy expenditure. Activating all three at once means the body is eating less and burning more simultaneously — a fundamentally different mechanism profile from earlier metabolic peptides.
The largest Phase 3 trial programme any metabolic peptide is currently running. Multiple parallel trials covering obesity, type 2 diabetes, knee osteoarthritis (with weight-related joint pain), obstructive sleep apnea, cardiovascular outcomes, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH).
The glucagon receptor is what makes Retatrutide distinctive. Research suggests glucagon activation increases the body's baseline metabolic rate — meaning more energy is burned even at rest. This is the mechanism behind the larger weight effects compared to dual-agonist or single-agonist compounds.
TRIUMPH-4 (December 2025) examined adults with obesity and knee osteoarthritis over 68 weeks, with the highest dose producing 28.7% mean body-weight reduction. TRIUMPH-1 (May 2026) followed in 2,339 participants over 80 weeks: 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, all doses meeting primary and key secondary endpoints. TRIUMPH-2 and TRIUMPH-3 reported in July 2026, with up to 22.6% at 80 weeks in participants with severe obesity and established cardiovascular disease.
In Phase 2 research in type 2 diabetes patients, Retatrutide produced 16.9% mean weight loss after 36 weeks alongside HbA1c improvements of 2.2% — with 82% of participants reaching the diabetes-control threshold of HbA1c ≤ 6.5%. Research suggests the combined metabolic effects extend beyond weight to comprehensive glycaemic control.
Retatrutide includes a fatty diacid side chain that allows the molecule to bind reversibly to albumin in the bloodstream. Research suggests this extends the circulating half-life to approximately 6 days — long enough that once-weekly dosing reaches stable levels. The same engineering approach used in Semaglutide and Tirzepatide, applied here to a more complex triple-target peptide.
How Retatrutide Works
The big-picture answer first: Retatrutide activates three hormone receptors simultaneously, two of which reduce energy intake (GIP and GLP-1) and one of which increases energy expenditure (glucagon). The combination addresses both sides of the body weight equation through a single peptide.
The GIP and GLP-1 pathways: these are the pathways inherited from the Tirzepatide story. GIP and GLP-1 are gut hormones the body releases after meals. Research suggests their receptors, when activated, slow gastric emptying (food stays in the stomach longer, prolonging fullness), enhance insulin secretion in proportion to food consumed, and send appetite-suppressing signals to the brain. Tirzepatide demonstrated the dual-pathway approach worked. Retatrutide preserves it.
The glucagon pathway is what is new: glucagon has historically been treated as the opposite of insulin — the hormone that releases stored glucose into the bloodstream. But research has shown that glucagon receptor activation also increases the body's baseline metabolic rate, encouraging the breakdown of stored fat for energy. Research suggests adding glucagon receptor activity to GIP and GLP-1 produces an effect neither pathway alone can match: the body is simultaneously receiving "you are full, eat less" signals from two receptors and "burn what you have" signals from a third.
The relative potency story: Retatrutide is not equally potent at all three receptors. Research suggests it is approximately 8.9 times more potent at the human GIP receptor than the natural hormone, and roughly 0.3–0.4 times as potent at the GLP-1 and glucagon receptors. The molecule was specifically engineered to produce this asymmetric profile — the strongest activity at GIP, balanced activity at GLP-1 and glucagon. Research suggests this calibration produces the desired metabolic effects without overwhelming any one pathway.
The structural engineering: Retatrutide is a 39-amino-acid synthetic peptide built on a GIP backbone with non-natural amino acid substitutions and a C20 fatty diacid side chain. The fatty diacid binds reversibly to albumin in the bloodstream, which research suggests extends the circulating half-life to about 6 days — long enough for once-weekly dosing. This is the same albumin-binding engineering approach used in Semaglutide and Tirzepatide, scaled up for the more complex triple-receptor activity profile.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated August 2026.
Published References
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.” The New England journal of medicine, 2023. PubMedThe pivotal Phase 2 obesity trial that established Retatrutide as the most potent metabolic peptide in clinical development. Reported up to 24.2% weight reduction at 48 weeks — the result that made the compound a research benchmark for triple-agonist development.
- Rosenstock J, Frias J, Jastreboff AM, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet (London, England), 2023. PubMedThe Phase 2 trial in type 2 diabetes patients — reported 16.9% weight loss at 36 weeks alongside HbA1c improvements of 2.2%, with 82% of participants reaching the diabetes-control threshold. Established the metabolic effects extend beyond weight to comprehensive glycaemic control.
- Sanyal AJ, Kaplan LM, Frias JP, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature medicine, 2024. PubMedExamined Retatrutide in patients with MASLD/MASH (formerly NAFLD/NASH) — liver disease driven by metabolic dysfunction. Reported substantial reductions in liver fat content alongside the body weight effects, suggesting the metabolic benefit extends to liver-specific outcomes.
- Coskun T, Urva S, Roell WC, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell metabolism, 2022. PubMedThe molecular pharmacology paper from the Eli Lilly discovery programme — explains the engineering of the asymmetric receptor potency profile (8.9x stronger at GIP than the natural hormone, 0.3–0.4x at GLP-1 and glucagon). Important reading for understanding the design choices behind the compound.
- Goldney J, Hamza M, Surti F, et al. “Triple Agonism Based Therapies for Obesity.” Current cardiovascular risk reports, 2025. SourceA 2025 review summarising the entire triple-agonist research category — useful as a starting point for understanding where Retatrutide sits relative to other triple-agonist compounds in development and where the field is heading.
Browse all Retatrutide research on PubMed →
Related Research Guides
More in Metabolic Research
The dual-agonist predecessor to Retatrutide — same Eli Lilly metabolic peptide programme, two receptors instead of three, with full FDA approval. The reference compound Retatrutide trials are designed against.
Read guide →Amylin AnalogueTargets appetite through a completely different pathway — the amylin receptor. Often studied alongside the GIP/GLP-1 family because the two pathways appear to work on complementary metabolic signalling systems.
Read guide →Exercise MimeticA mitochondrial peptide that activates AMPK — the cellular energy sensor. A different angle on metabolic research, focused on energy production at the cellular level rather than appetite signalling.
Read guide →